Dr. Erik Eglite Joins as Vice President, Chief Compliance Officer and Corporate Counsel; Eric J. Messner Joins as Vice President, Sales and Marketing
NORTHBROOK, Ill. – July 27, 2016 – Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced that it has made two senior additions to its executive team.
Dr. Erik Eglite
In his new role as Vice President, Chief Compliance Officer and Corporate Counsel, Dr. Erik Eglite will be responsible for the company’s compliance matters. He brings more than a decade of experience working in this critical function.
Prior to joining Marathon, Dr. Eglite served as Vice President, Chief Compliance Officer and Corporate Counsel for Lundbeck Pharmaceuticals. Prior to Lundbeck, he was Vice President, Chief Compliance Officer and Corporate Counsel for Ovation Pharmaceuticals and Global Chief Compliance Officer for Aspreva Pharmaceuticals.
“Erik’s extensive legal and compliance background, coupled with his knowledge of the pharmaceutical industry, makes him an ideal fit as our Chief Compliance Officer,” said Jeff Aronin, Chief Executive Officer, Marathon Pharmaceuticals. “For Marathon to succeed long term, we need to operate from a strong foundation of values supported by an effective compliance program. I look forward to working with Erik and the executive team to uphold the highest standards of integrity in our service to patients and the community.”
Dr. Eglite is a licensed podiatric physician and surgeon and is registered to practice law before the Unites States Patent and Trademark Office, the United States Court of Appeals for the Federal Circuit, the United States Court of Appeals for the District of Columbia Circuit and the United States Seventh Circuit Court of Appeals.
Dr. Eglite has an MBA from the University of Notre Dame, an M.Sc in Chemistry and a J.D. from Loyola University of Chicago. He graduated from Des Moines University Iowa Medical School with a Doctorate in Podiatric Medicine and Surgery. He holds a graduate certificate in Pharmaceutical and Medical Device Law from Seton Hall School of Law, an Executive Certificate in Corporate Governance from Northwestern University Kellogg School of Management and an Executive Certificate in Business Administration from the University of Notre Dame.
Eric J. Messner
Mr. Eric J. Messner joins Marathon as Vice President, Sales and Marketing and will lead the company’s sales, marketing and managed care strategy and execution. Prior to joining Marathon, Mr. Messner was CEO of Anagin, LLC, which develops drugs for post-traumatic stress disorder and traumatic brain injury.
Mr. Messner has enjoyed a long and successful career in the pharmaceutical industry. Prior to Anagin, LLC, he served as General Manager and Executive Vice President of Sales and Marketing for OPKO Health, where he had commercial responsibility for the renal division and urology laboratory division. Earlier in Mr. Messner’s career he was a founder and Vice President of Marketing and Commercial Operations of Proventiv Therapeutics, which was acquired by Cytochroma. At Cytochroma, he was Vice President of Commercial Operations and later the Chief Operating Officer, assisting in the sale of Cytochroma to OPKO Health. Mr. Messner also held senior marketing roles at Bone Care International and Abbott Laboratories.
“Eric’s breadth of experience in developing and executing integrated strategies to drive growth represents a key addition to our executive team,” said Jeff Aronin. “I am pleased to have a leader of Eric’s caliber on board to drive our sales and marketing efforts. He will be instrumental in contributing to our vision, strategy and overall growth, and his skills in identifying opportunities, setting direction and building external relationships will contribute substantially to our long-term success.”
Mr. Messner holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor of Science in Business Administration from Miami University.
About Marathon Pharmaceuticals
Marathon Pharmaceuticals, LLC, is a biopharmaceutical company that develops treatments for rare diseases, with a focus on patients who currently have no treatment options. The company’s pipeline of new medicines includes treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.
